Hong Green, Ju Hyekyeong, Oh Dong Kyu, Lee Su Yeon, Park Mi Hyeon, Lee Haein, Lim Chae-Man, Lee Song I
Division of Allergy, Pulmonary, and Critical Care Medicine, Department of Internal Medicine, Chungnam National School of Medicine, Chungnam National University Hospital, Munhwaro 282, Jung Gu, Daejeon, 35015, Republic of Korea.
Department of Pulmonary and Critical Care Medicine, Dongkang Medical Center, Ulsan, Republic of Korea.
Sci Rep. 2025 Feb 27;15(1):7078. doi: 10.1038/s41598-025-87457-y.
Sepsis is a severe complication in patients with malignant tumors, leading to high mortality and increased need for intensive care. This study aimed to investigate the clinical characteristics and prognostic factors influencing sepsis outcomes in patients with malignant tumors. We included 4,858 patients with cancer diagnosed with sepsis between September 2019 and February 2020 whose data were collected from the Korean Sepsis Alliance, a nationwide multicenter cohort study. Cox regression analysis was used to identify predictors of 30-day and in-hospital mortality. In total, 65% of the patients survived, whereas 35% did not. Non-survivors were more likely to require intensive care, including mechanical ventilation and continuous renal replacement therapy. Key predictors of mortality included renal dysfunction, higher Sequential Organ Failure Assessment scores, and reliance on life-sustaining treatments. Non-survivors exhibited lower adherence to the implementation of sepsis care bundles, particularly to later-stage interventions. Gram-negative bacterial infections and multidrug resistance were more prevalent in non-survivors, complicating treatment efficacy. In conclusion, tailored treatment strategies that consider specific patient characteristics and disease dynamics are needed in managing sepsis with malignancy. Early identification and treatment of organ dysfunction, coupled with strict adherence to sepsis treatment protocols, are critical to improving survival in this population.
脓毒症是恶性肿瘤患者的一种严重并发症,导致高死亡率并增加了重症监护需求。本研究旨在调查恶性肿瘤患者脓毒症的临床特征及影响脓毒症预后的因素。我们纳入了2019年9月至2020年2月期间被诊断为脓毒症的4858例癌症患者,其数据来自韩国脓毒症联盟,这是一项全国性多中心队列研究。采用Cox回归分析来确定30天和住院死亡率的预测因素。总体而言,65%的患者存活,而35%的患者未存活。非存活者更有可能需要重症监护,包括机械通气和连续性肾脏替代治疗。死亡率的关键预测因素包括肾功能不全、较高的序贯器官衰竭评估评分以及对维持生命治疗的依赖。非存活者对脓毒症护理集束的实施依从性较低,尤其是对后期干预措施。革兰氏阴性菌感染和多重耐药在非存活者中更为普遍,使治疗效果复杂化。总之,在管理恶性肿瘤合并脓毒症时,需要考虑特定患者特征和疾病动态的定制治疗策略。早期识别和治疗器官功能障碍,以及严格遵守脓毒症治疗方案,对于提高该人群的生存率至关重要。